Related to EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk

• Amylin and Lilly’s Byetta Sanctioned as Monotherapy for Type 2 Diabetes
  
• Japan Sanctions Three Novartis Drugs for Hypertension, Advanced Renal Cancer, and Type 2 Diabetes
  
• Novo Nordisk Gains Approval for Type 2 Diabetes Treatment in Japan
  
• Novo Nordisk’s Type 2 Diabetes Drug Green-Lighted by FDA
  
• FDA Stalls Approval of Amylin, Lilly, and Alkermes’ Type 2 Diabetes Therapy
  
• Tarceva Gains EC Clearance as Maintenance Therapy in NSCLC
  
• T2cure’s Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification
  
• Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk
  
• CHMP Doles Out Two Positive Opinions on Archimedes Pharma and Merck & Co. Drugs
  
• Published Studies Uphold Health Risk Concerns about GSK’s Type 2 Diabetes Drug
  
• Nycomed’s Anti-Inflammatory Gains Approval in EU for COPD
  
• EC Clears BMS’ Orencia for Earlier Use in Treating RA
  
• Asuragen and Life Technologies Launch BCR/ABL1 Quant Leukemia Test in Europe
  
• GSK Halts Enrollment for Postmarketing Avandia Trial as FDA Reviews Safety
  
• Investigators Find Pathway that May Better Explain How Antidiabetics Like Avandia Work
  
• Shire Gains EC Nod for Gaucher Disease Treatment
  
• EU Sanctions Merck & Co.'s Sublingual Bipolar Disorder Drug Sycrest
  
• FDA Significantly Restricts Access to GSK’s Antidiabetic Avandia
  
• EMEA Urges Withdrawal of Octapharma’s IV Immunoglobulin due to Serious Adverse Events
  
• Progenika Gets CE Mark for LPL Gene Chip for Use with AMT’s Gene Therapy